ClinicalTrials.gg
CompletedNCT01367002Updated May 17, 2023Results posted

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

A Phase 2 interventional study of Carboplatin/Paclitaxel and Trastuzumab in Endometrial Cancer, sponsored by Yale University. Completed at 20 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Enrollment
289th of 591
61 · median 60
Started
2011
with 13 others
Phase 2
178 of 715
34 open now
Registered
176th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 289th largest by enrollment of the 591 interventional ones that give a count, is one of 14 that started in 2011, is one of 178 in phase 2, and was the 176th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine Serous Papillary Carcinoma (USPC) patients overexpressing Her2/neu at 3+ level by immunohistochemistry (IHC)or positive by fluorescence in situ hybridization (FISH).

Read the detailed description

The purpose of this study is to perform a randomized Phase II evaluation of Carboplatin/Paclitaxel with or without Trastuzumab (Herceptin) in patients with HER2/neu+ advanced stage/recurrent disease with an emphasis on determining the progression free survival in USPC patients and assessing immunologic markers predictive of trastuzumab response.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Uterine serous papillary carcinoma
  • Type II endometrial cancer
  • HER2/neu
  • Paclitaxel, Carboplatin, Trastuzumab
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have advanced (stage III-IV) or recurrent confirmed USPC with .
  • Patients must harbor a tumor /neu+ based upon IHC staining score of 3+ or 2+ with confirmed gene amplification by FISH

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of other invasive , with the exception of non-melanoma skin cancers, significant history of cardiac disease, uncontrolled hypertension, unstable medical issue, brain , prior therapy with trastuzumab, uncontrolled seizure disorder, seropositive for , active hepatitis, hemorrhagic diathesis or requiring supplemental oxygen.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Active comparator
    Carboplatin/Paclitaxel

    Chemotherapy

    Drug: Carboplatin/Paclitaxel

  • Experimental
    Trastuzumab

    Monoclonal antibody

    Drug: Trastuzumab

Interventions

  • DrugCarboplatin/Paclitaxel

    Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.

    Also known as: Taxus brevifolia, cis-Diammine

  • Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival Differences Between Treatment Arms.

    Progression free survival differences between treatment arms.

    Time frame: 6 years

Secondary outcomes

  1. To Assess the Safety Profile of Trastuzumab in USPC Patients by CTCAE v4.0

    To assess the safety profile of trastuzumab in USPC patients by CTCAE v4.0. Presented are counts of those that experience any Serious Adverse Events or All Other Adverse Events.

    Time frame: 6 years

  2. To Assess Objective Response Rate (ORR)

    To assess objective response rate (ORR)

    Time frame: 6 years

  3. To Assess Overall Survival (OS)

    To assess overall survival (OS), presented are the number of participants that survived through the duration of the study period.

    Time frame: 6 years

07

Results

Posted Apr 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneCarboplatin/PaclitaxelTrastuzumab
Started2932
Participants receive drug2832
Participants evaluable for pfs2830
Completed2830
Not completed12
Withdrew: Withdrawal by subject10
Withdrew: Physician decision02

Outcome measures

PrimaryProgression Free Survival Differences Between Treatment Arms.

Progression free survival differences between treatment arms.

Time frame:
6 years
Reported as:
Median · months
Progression Free Survival Differences Between Treatment Arms.
monthsCarboplatin/PaclitaxelTrastuzumab
Progression Free Survival Differences Between Treatment Arms.8.049 (7.129 to 9.692)12.945 (10.448 to 18.103)
SecondaryTo Assess the Safety Profile of Trastuzumab in USPC Patients by CTCAE v4.0

To assess the safety profile of trastuzumab in USPC patients by CTCAE v4.0. Presented are counts of those that experience any Serious Adverse Events or All Other Adverse Events.

Time frame:
6 years
Reported as:
Count of participants · Participants
To Assess the Safety Profile of Trastuzumab in USPC Patients by CTCAE v4.0
ParticipantsCarboplatin/PaclitaxelTrastuzumab
Serious Adverse Events614
All Other Adverse Events2832
SecondaryTo Assess Objective Response Rate (ORR)

To assess objective response rate (ORR)

Time frame:
6 years
Reported as:
Count of participants · Participants
To Assess Objective Response Rate (ORR)
ParticipantsCarboplatin/PaclitaxelTrastuzumab
Complete Response (CR)21
Partial Response (PR)43
Stable Disease (SD)15
Progressive Disease (PD)10
SecondaryTo Assess Overall Survival (OS)

To assess overall survival (OS), presented are the number of participants that survived through the duration of the study period.

Time frame:
6 years
Reported as:
Count of participants · Participants
To Assess Overall Survival (OS)
ParticipantsCarboplatin/PaclitaxelTrastuzumab
To Assess Overall Survival (OS)79

Adverse events

Collected over 30 days post treatment (treatment could last as long as 6 years). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboplatin/Paclitaxel21/28 (75%)6/28 (21.4%)28/28 (100%)
Trastuzumab21/32 (65.6%)14/32 (43.8%)32/32 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventCarboplatin/PaclitaxelTrastuzumab
Allergic reactionImmune system disorders0/282/32
Abdominal painGastrointestinal disorders0/282/32
Small intestinal obstructionGastrointestinal disorders1/282/32
Blood and lymphatic system disorders - OtherBlood and lymphatic system disorders1/280/32
Febrile neutropeniaBlood and lymphatic system disorders1/280/32
HyperglycemiaMetabolism and nutrition disorders1/281/32
Renal and urinary disorders - OtherRenal and urinary disorders1/280/32
Reproductive system and breast disorders - OtherReproductive system and breast disorders1/280/32
Thromboembolic eventVascular disorders1/281/32
GastroparesisGastrointestinal disorders1/280/32
Most frequent other events
Showing 10 of 190
Most frequent other events
EventCarboplatin/PaclitaxelTrastuzumab
FatigueGeneral disorders17/2823/32
NauseaGastrointestinal disorders11/2818/32
Peripheral sensory neuropathyNervous system disorders15/2817/32
ConstipationGastrointestinal disorders9/2817/32
AnemiaBlood and lymphatic system disorders13/2816/32
AlopeciaSkin and subcutaneous tissue disorders14/2815/32
Abdominal painGastrointestinal disorders3/2816/32
DiarrheaGastrointestinal disorders5/2813/32
Neutrophil count decreasedInvestigations9/2811/32
HypertensionVascular disorders5/2811/32

Baseline characteristics

Only those evaluable for PFS are included. Three were excluded due to: withdrawal of consent (n = 1) or failure to confirm HER2 positivity by fluorescence in situ hybridization (FISH) after 2+ immunohistochemistry (n = 2).

Age, Continuous
Age, Continuous(years)Carboplatin/PaclitaxelTrastuzumabTotal
Median73 (45 to 88)67 (57 to 85)69 (45 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)Carboplatin/PaclitaxelTrastuzumabTotal
Female283058
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carboplatin/PaclitaxelTrastuzumabTotal
Hispanic or Latino134
Not Hispanic or Latino262652
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Carboplatin/PaclitaxelTrastuzumabTotal
American Indian or Alaska Native101
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American81018
White172037
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Carboplatin/PaclitaxelTrastuzumabTotal
United States283058
Disease Status
Disease Status(Participants)Carboplatin/PaclitaxelTrastuzumabTotal
Advanced202141
Recurrent8917
08

Study locations

20 sites
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • John Muir Clinical Research Center
    Concord, California 94520, United States
  • Women's Cancer Research Foundation
    Newport Beach, California 92663, United States
  • Penrose St. Francis Hospital
    Colorado Springs, Colorado 80907, United States
  • Danbury Hospital
    Danbury, Connecticut 06810, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06030, United States
  • The Hospital of Central Connecticut
    New Britain, Connecticut 06050, United States
  • Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut 06510, United States
  • The University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889-5600, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20910, United States
  • University of Maryland Medical Center
    Silver Spring, Maryland 20910, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Duke University School of Medicine
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Hilliard, Ohio 43026, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
09

References and documents

Publications

  • Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002 May;8(5):1271-9. PubMed 12006548 ↗
  • Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005 Mar;192(3):813-8. doi: 10.1016/j.ajog.2004.10.605. PubMed 15746676 ↗
  • Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005 Jul;98(1):24-30. doi: 10.1016/j.ygyno.2005.03.041. PubMed 15894362 ↗
  • Santin AD. Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010). Gynecol Oncol. 2010 Jul;118(1):95-6; author reply 96-7. doi: 10.1016/j.ygyno.2010.01.043. Epub 2010 Feb 20. No abstract available. PubMed 20172595 ↗
  • Schwartz PE. The management of serous papillary uterine cancer. Curr Opin Oncol. 2006 Sep;18(5):494-9. doi: 10.1097/01.cco.0000239890.36408.75. PubMed 16894299 ↗
  • Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000 Apr;77(1):55-65. doi: 10.1006/gyno.2000.5737. PubMed 10739691 ↗
  • Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994 Sep;54(3):264-8. doi: 10.1006/gyno.1994.1208. PubMed 8088602 ↗
  • Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA; Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44. doi: 10.1200/JCO.2004.00.7617. Epub 2005 Dec 5. PubMed 16330675 ↗
  • Burke TW, Gershenson DM, Morris M, Stringer CA, Levenback C, Tortolero-Luna G, Baker VV. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994 Oct;55(1):47-50. doi: 10.1006/gyno.1994.1245. PubMed 7959265 ↗
  • Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh JJ, Wharton JT. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol. 1992 Sep;46(3):317-21. doi: 10.1016/0090-8258(92)90224-7. PubMed 1526508 ↗
  • Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Aug;62(2):278-81. doi: 10.1006/gyno.1996.0227. PubMed 8751561 ↗
  • Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Mar;88(3):277-81. doi: 10.1016/s0090-8258(02)00068-9. PubMed 12648575 ↗
  • Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66. doi: 10.1200/JCO.2004.07.184. PubMed 15169803 ↗
  • Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 Jul;82(1):156-61. doi: 10.1006/gyno.2001.6211. PubMed 11426978 ↗
  • Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987 Oct 15;60(8 Suppl):2035-41. doi: 10.1002/1097-0142(19901015)60:8+3.0.co;2-8. PubMed 3652025 ↗
  • Tymon-Rosario J, Siegel ER, Bellone S, Harold J, Adjei N, Zeybek B, Mauricio D, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Azodi M, Schwartz PE, Fader AN, Santin AD. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecol Oncol. 2021 Oct;163(1):93-99. doi: 10.1016/j.ygyno.2021.07.033. Epub 2021 Aug 6. PubMed 34372971 ↗
  • Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. PubMed 29584549 ↗
  • Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. PubMed 32601075 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jun 2022 and a completion of Jun 2022. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2023, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2011
First posted
Jun 6, 2011
Start
Jun 2011
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Results first posted
Apr 18, 2023
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01367002
Lead sponsor
Yale University
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 6, 2011
Start date
Jun 2011
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Results posted
Apr 18, 2023
Last update
May 17, 2023

Study contacts

Alessandro D Santin, M.D.
principal investigator · Yale University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion